12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

InflammaGen Shok-Pak: Phase II started

InflammaGen Therapeutics Inc., part of Leading BioSciences, began a double-blind, U.S. Phase II trial to compare InflammaGen Shok-Pak vs. standard therapy in about 200 critically-ill ICU...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >